Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359415 | 0.83 | HPGD (0.56) | NAMPTALDH1A1HPGDTSHRMAPT | |
| SCHEMBL3210271 | 0.83 | L3MBTL1 (0.44) | L3MBTL1NAMPTNPC1 | |
| SCHEMBL5321672 | 0.81 | MAPK1 (0.47) | NAMPTNPC1 | |
| SCHEMBL5332752 | 0.81 | TP53 (0.48) | L3MBTL1NAMPTALDH1A1KDM4E | |
| SCHEMBL16707667 | 0.78 | FKBP1A (0.49) | NAMPTLMNAALDH1A1HPGDMAPT | |
| SCHEMBL5322483 | 0.76 | NAMPT (0.43) | L3MBTL1NAMPT | |
| SCHEMBL5322490 | 0.76 | GPR142 (0.46) | NAMPTLMNAALDH1A1KDM4E | |
| SCHEMBL5323146 | 0.76 | ALDH1A1 (0.49) | NAMPTLMNAALDH1A1TSHRMAPT | |
| SCHEMBL5330616 | 0.75 | ALDH1A1 (0.44) | L3MBTL1NAMPTLMNAALDH1A1TSHR | |
| SCHEMBL16707783 | 0.74 | ADRB2 (0.49) | L3MBTL1NAMPTLMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | L3MBTL1 4465/4885NAMPT 1474/4885LMNA 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.